TABLE 1.

Prognostic roles of the ARGs signature with different demographic and clinical characteristics in TCGA training set (OS).

Characteristics	Number (high-/low-risk group)	%	HR (95% CI)	P-value
Age (years)
≥65	130/141	55.3%	2.062 (1.357–3.132)	0.001
<65	115/104	44.7%	1.636 (0.995–2.690)	0.052
Sex
Female	122/144	54.3%	1.516 (0.978–2.349)	0.063
Male	123/101	45.7%	2.347 (1.435–3.839)	0.001
Stage
I	109/152	53.3%	1.329 (0.772–2.288)	0.306
II	69/48	23.9%	1.844 (0.994–3.422)	0.052
III	49/30	16.1%	2.290 (1.122–4.671)	0.023
IV	14/11	5.1%	1.450 (0.482–4.355)	0.508
NA	4/4	1.6%	−	−
T stage
T1	59/107	33.9%	1.420 (0.751–2.686)	0.280
T2	145/113	52.7%	1.866 (1.206–2.889)	0.005
T3	29/16	9.2%	5.638 (1.261–25.205)	0.024
T4	11/7	3.7%	1.274 (0.316–5.138)	0.733
NA	1/2	0.6%	−	−
M stage
M0	173/149	65.7%	1.847 (1.241–2.747)	0.002
M1	14/10	4.9%	1.699 (0.520–5.549)	0.380
NA	58/86	29.4%	−	−
N stage
N0	144/173	64.7%	1.622 (1.01902.583)	0.042
N1	53/39	18.8%	1.523 (0.834–2.781)	0.171
N2	43/25	13.9%	2.264 (1.063–4.825)	0.034
N3	1/1	0.4%	−	−
NA	4/7	2.2%	−	−

NA, not available; HR, hazard ratio; CI, confidence interval; OS, overall survival.